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BisphosphonatesAbstract Fractures of severely atrophic (height < 10 mm) edentulous mandibles are infrequent and
challenging to manage. Factors such as sclerotic bone and decreased vascularity combined with sys-
temic diseases complicate the management of such fractures. Osteogenesis imperfecta (OI) is a heter-
ogeneous group of inherited disorders of type I collagen metabolism. Patients with OI
characteristically presentwithhistories of longbone fractures, deformities, blue sclerae, andopalescent
dentin. However, fractures of the facial skeleton are rare. Bisphosphonate therapy has been proven to
effectively reduce the fracture risk in patientswithOI.Thepurpose of this clinical report is to present an
unusual case of spontaneous fracture of the atrophic mandible in a patient with OI. Despite open
reduction and internal ﬁxation (ORIF) with miniplate osteosynthesis, the patient developed a second
fracture at a screw placement site distal to the ﬁrst fracture. The patient was successfully treated with
ORIF using locking reconstruction plates ﬁxed in the symphyseal and angle regions. Bone healing fol-
lowing ORIF was normal, and no clinical sign of osteonecrosis as a result of bisphosphonate therapy
was observed. Patients with OI can present with spontaneous fractures of already weakened mandi-
bles. Although such fractures can be managed with care using established protocols, further research
is required to examine the effects of concomitant medication, such as bisphosphonates.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Mandibular atrophy due to edentulism leads to decreased bone
mass and increased vulnerability to fracture (Ellis and Price,
2008). Fractures of the atrophic edentulous mandible are not
common and present challenges to the clinician in terms of
reduction and immobilization of the fracture site (Ellis and
Price, 2008; Melo et al., 2011). Such fractures occur more
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logic changes affect bone repair negatively. Local factors, such
as dense cortical bone and inadequate blood supply, combined
with an increased risk of systemic disease in this population,
further complicate the outcomes of treatment (Ellis and Price,
2008; Eyrich et al., 1997; Wittwer et al., 2006). Although falls
are the main etiologic events leading to fracture of the atrophic
mandible, the placement of implants and interpersonal assault
have also been reported (Ellis and Price, 2008; Melo et al.,
2011; Mugino et al., 2005; Raghoebar et al., 2000). The basic
principle of treatment for these fractures is to restore the ana-
tomic form and function by reduction and immobilization of
the fracture segments. Treatment options reported in the liter-
ature are controversial (Barber, 2001; Eyrich et al., 1997;
Marciani, 2001; Wittwer et al., 2006). Unfavorable results
associated with conservative management have shifted the fo-
cus toward open surgical treatment of atrophic mandibular
fractures. Open reduction and internal ﬁxation (ORIF) enables
free movement of the mandible during speech and mastication.
Nevertheless, treatment depends on the systemic status of the
patient and the degree of fracture displacement (Eyrich
et al., 1997; Luhr et al., 1996; Melo et al., 2011).
Osteogenesis imperfecta (OI), also referred to as ‘‘brittle
bone’’ disease, is an inherited connective tissue disorder char-
acterized by bone fragility. The overall incidence of OI is
approximately one in 10,000 births (Huber, 2007). It is known
to be inherited both dominantly and recessively, and is due to a
mutation in the genes responsible for procollagen synthesis
(Table 1). The disease is caused by the production of abnormal
matrix by osteoblasts, which fails to withstand mechanical
loads adequately (Gallego et al., 2010; Huber, 2007). Patients
with OI are susceptible to fractures in response to mild trauma
or even occurring spontaneously. Fractures of the extremities
are encountered frequently, but facial bone fractures are rela-
tively rare (Feifel, 1996; Gallego et al., 2010). Treatment of OI
is essentially palliative and is aimed at reducing fractures and
improving the quality of life. In the past decade, however, bis-
phosphonates have been used to alleviate bone pain and
reduce fracture risk in patients with OI (Landesberg et al.,Table 1 Types of osteogenesis imperfecta (Huber, 2007).
Types Clinical features
I* Normal stature with bone fragility and blue sclera
First fractures when learning to walk or stand. Ambulatory wi
Associated with sensorineural deafness >50%
II* Severe bone fragility and lethal either in utero or in the perinat
Associated with cardio-pulmonary insuﬃciency
New borns exhibit blue sclera, soft calvarial bones, triangular f
III* Short stature due to progressive deformity and a high fracture
Enlarged head with deformation of bone at the base of the sku
Early hearing loss and variable sclera
IV* Short stature with bowing of legs
Progressive impairment of mobility
Normal sclera with variable hearing loss
V# Mild to moderate stature with dislocation of the head of the ra
Associated with hyperplastic callus formation and white sclera
VI# Scoliosis with moderate stature and white sclera
VII# Bone fragility at birth with rhizomelia, coxa vara, osteopenia a
* Originally classiﬁed by Sillence et al. (1979).
# Recently added uncommon types by Glorieux et al. (2000); Glorieux2009; Rauch and Glorieux, 2005). Bisphosphonates are a po-
tent group of drugs that target osteoclasts, resulting in reduced
bone resorption. Their use to manage osteoblast disorders,
such as OI, is based on the hypothesis that a reduction in bone
resorption might compensate for the weakness in bone forma-
tion and reduce the development of osteoporosis due to disuse
(Gallego et al., 2010; Rauch and Glorieux, 2005). Moreover,
their effects on bone turnover may lead to bisphosphonate re-
lated osteonecrosis of the jaws (BRONJ) following oral surgi-
cal procedures (Heufelder et al., 2012; Ruggiero et al., 2009).
Here, we report a case of spontaneous atrophic mandibular
fracture in an adult patient with type I OI receiving oral bis-
phosphonate treatment. To our knowledge, this presentation
of atrophic mandibular fracture concomitant with systemic
bone disorder is unusual. We describe the failed treatment of
the fracture with miniplate osteosynthesis and successful
retreatment with locking mandibular reconstruction plate oste-
osynthesis. In spite of the potential risk of developing BRONJ,
the bone healing following fracture retreatment was unremark-
able and no clinical sign of osteonecrosis was observed.
2. Case report
In June 2011, a 48-year-old male Saudi patient was referred to
the Oral and Maxillofacial Surgery Clinic at King Saud Med-
ical Complex, Riyadh, Kingdom of Saudi Arabia. On presen-
tation, the patient complained of numbness in his lower lip
associated with discomfort in the right mandible for 3 weeks.
He had no history of trauma or injury. His medical history re-
vealed a diagnosis of type I OI based on the Sillence et al. clas-
siﬁcation (Sillence et al., 1979). The patient had undergone
multiple orthopedic surgical interventions for spontaneous
lower extremity fractures, including retreatment of a non-uni-
ted tibial fracture, which necessitated bone graft placement.
The last surgical intervention had been performed 18 months
previously. The patient had also been diagnosed with osteopo-
rosis 8 years previously, and since that time had received treat-
ment with oral alendronic acid (Fosamax, 70 mg once/week;
Merck, Whitehouse Station, NJ, USA), alfacalcidolPrevalence Mode of inheritance
1: 15,000–20,000 AD
th no bowing of legs
al period 1: 20,000–60,000 AD; AR (rare)
ace and beaked nose
rate 1: 50,000–100,000 AD; AR (rare)
ll and triangular facies
Unknown AD
dius Unknown AR
Unknown AR
nd blue sclera Unknown AR
et al. (2002) and Ward et al. (2002).
Figure 2 Post-operative panoramic radiograph (immediately
after ﬁrst surgery) showing miniplate ﬁxation of the right
mandibular body fracture with four screws placed on either side
of the fracture line.
Figure 3 Post-operative panoramic radiograph (3 weeks after
ﬁrst surgery) showing displacement of a screw and evidence of
undisplaced fracture distal to the site of primary fracture.
70 A. Al-Osaimi et al.(One-Alpha, 1 lg/day; Leo Pharmaceutical Products, Ball-
erup, Denmark), and calcium carbonate (Osteocare, 600 mg
twice/day; Vitabiotics, London, UK). The patient’s dental re-
cords showed a history of multiple uncomplicated dental
extractions, a completely edentulous mandibular arch, and a
normal C-terminal telopeptide (CTX) reading. CTX testing
had been performed before 1 month, as the patient sought den-
tal implant rehabilitation due to an ill-ﬁtting lower denture.
Clinical examination revealed reduced mobility of the man-
dible associated with pain in the right mandibular body region
and anesthesia of tissues along the distribution of the right
mental nerve. Radiographic examination showed fracture of
the right mandibular body with gross displacement (Fig. 1).
The patient consented to and was prepared for ORIF of the
fracture under general anesthesia. Surgical exposure of the
fracture site was achieved using an extraoral submandibular
approach. Upon exposure, the mandible was found to be se-
verely atrophic (class III; height, 9 mm) and the right inferior
neurovascular bundle was found to be completely transected.
Anatomic ORIF of the mandibular body fracture was per-
formed with a 2.0-mm miniplate (Mini-System; KLS Martin,
Tuttlingen, Germany) and four self-drilling screws (9-mm
maxDrive drill-free screws; KLS Martin), which were placed
on either side of the fracture line at the inferior border of
the mandible (Fig. 2). The postoperative period was uneventful
and after completion of a short-term intravenous (IV) antibi-
otic course (cephradine, 500 mg every 6 h, and metronidazole,
500 mg every 8 h, for 5 days), the patient was discharged with a
prescription for oral antibiotics (clindamycin, 300 mg every 8 h
for 5 days) and strict advice to maintain a liquid diet for
4 weeks and to discontinue the use of any denture or
prosthesis.
Three weeks after the ﬁrst surgery, the patient presented to
the emergency department of King Saud Medical Complex
immediately after hearing a cracking sound at the surgical site.
Clinical examination revealed moderate tenderness at the sur-
gical site with diffuse extraoral edema. Radiographic examina-
tion showed a displaced screw and a new fracture in the distal
segment of the old fracture (Fig. 3). The patient consented to
and was prepared for a second surgical procedure under gen-
eral anesthesia. The previous ORIF site was exposed using
the same approach. Comminution at the new fracture site
and callus formation at the old fracture site were observed
upon exposure. Fixation was performed using a 2.4-mm lock-
ing mandibular reconstruction plate (Compact 2.4 UniLOCK;Figure 1 Pre-operative panoramic radiograph showing fracture
of the atrophic mandible with displacement in the right mandib-
ular body region.Synthes, Oberdorf, Germany) and bicortical self-drilling
screws (14-mm UniLOCK screws; Synthes), which were placed
in the more stable mandibular ramus and symphyseal regions
(Fig. 4). The postoperative period was uneventful and the pa-
tient was given an IV antibiotic regimen (cephradine, 500 mg
every 6 h, and metronidazole, 500 mg every 8 h) for 7 days.
The patient was then discharged with a prescription for oral
antibiotics (clindamycin, 300 mg every 8 h for 2 weeks) and ad-
vised to follow a strict liquid diet for 4 weeks and return
monthly for follow-up clinical visits. A follow-up radiograph
taken 6 months postoperatively showed no appreciable frac-Figure 4 Post-operative panoramic radiograph (immediately
after second surgery) showing stable reduction and ﬁxation of
the right mandibular body fracture using a mandibular recon-
struction plate ﬁxed to the mandibular angle and symphysis
regions.
Figure 5 Post-operative postero-anterio view of the skull
(3 months after second surgery) showing stable ﬁxation of the
mandible and no evidence of osteonecrosis.
Atrophic mandible fracture in osteogenesis imperfecta 71ture line (Fig. 5). The patient has shown no clinical sign of
fracture non-healing or osteonecrosis during the past 2 years.
The patient provided informed consent to the publication
of this report and his radiographs. Ethical approval for the
publication of this case report was also obtained from the insti-
tutional ethics board.
3. Discussion
Following dental extraction, biological processes lead to the
loss of the alveolar ridge. The combined effects of tooth loss
and bone resorption result in an atrophic mandible that is vul-
nerable to fracture with increasing age (Madsen et al., 2009).
Ellis and Price (2008) deﬁned an atrophic mandible as any
mandible with a height <15 mm. Luhr et al. provided a more
comprehensive classiﬁcation of atrophic mandibles based on
height, consisting of classes I (height 16–20 mm), II (height
11–15 mm), and III (height 6 10 mm) (Luhr et al., 1996). Class
III atrophic mandibles are most susceptible to fracture, as the
region of least height is associated with the greatest fracture
frequency (Melo et al., 2011). In the present clinical case, the
patient had a class III atrophic mandible according to the Luhr
et al. classiﬁcation.
Despite the lack of conclusive evidence in the literature sup-
porting a conservative or surgical approach for the manage-
ment of fracture of an edentulous atrophic mandible
(Holland, 2007; Nasser et al., 2007), several studies have pro-
vided better support for the latter approach (Ellis and Price,2008; Eyrich et al., 1997; Madsen et al., 2009; Marciani,
2001). The recommended ﬁxation methods have been mini-
plate osteosynthesis (Clayman and Rossi, 2012; Melo et al.,
2011; Mugino et al., 2005) or the use of locking mandibular
reconstruction plates (Madsen et al., 2011; Santos et al.,
2013; Tiwana et al., 2009; Van Sickels and Cunningham,
2010). In a large series (335 patients) of mandibular fractures
reported by Mugino et al. (2005), 15 fracture sites in the eden-
tulous mandibles of 11 patients were all treated with miniplate
osteosynthesis. The authors recommended the placement of
two miniplates – one buccally and the other at the inferior bor-
der – in cases of extremely thin (height < 10 mm) mandibles.
Based on a series of 16 patients with edentulous mandibular
fractures, Clayman and Rossi (2012) afﬁrmed the safety and
effectiveness of ORIF with miniplates placed at the inferior
mandibular border. In the present case, the mandibular frac-
ture was treated in the ﬁrst instance using miniplate ﬁxation;
a 2.0-mm miniplate was selected based on the observations
of Wittwer et al. (2006), who recommended the most rigid ﬁx-
ation possible for mandibles with heights < 15 mm.
OI is an inherited disease that affects bone formation,
resulting in low bone mass and fragility. It can be divided into
four main types based on disease progression and severity (Hu-
ber, 2007) (Table 1). Type 1 OI, the most common form of the
disease, is characterized by vertebral and long bone fractures,
which begin with ambulation in childhood and are associated
with falls later in life. It is rarely deforming, and affected pa-
tients attain near-normal height. Commonly observed dental
anomalies associated with OI include dentinogenesis imperfec-
ta and malocclusion (Huber, 2007), and rare instances of man-
dibular fracture during dental extraction have also been
reported (Feifel, 1996; Gallego et al., 2010). Patients with OI
have reduced quantities of cortical and trabecular bone com-
pared with normal patients (Huber, 2007). Prolonged edentu-
lism leads to the reduction of the mandibular cross-sectional
area, ultimately decreasing the amount of internal buttressing
(Santos et al., 2013). All of these factors prompt the hypothesis
that the primary mandibular fracture in the present case,
which occurred in the absence of any fall, was due to the com-
bined effects of OI and the reduced load-bearing ability of the
atrophic mandible.
Within 3 weeks of ORIF using the 2.0-mm miniplate, the
patient presented with a secondary fracture distal to the pri-
mary fracture. This fracture occurred despite the patient’s
maintenance of a strict liquid diet in the postoperative period.
While the observation of callus formation at the primary frac-
ture site indicates the effectiveness of ORIF, comminution and
screw displacement at the secondary fracture site demonstrate
the weakening effect of OI on the already atrophic mandible.
The second ORIF was performed using 2.4-mm locking man-
dibular reconstruction plates, following the ﬁndings of Tiwana
et al. (2009) and Van Sickels and Cunningham (2010) that the
use of a large reconstruction plate and the thick bone in the
symphyseal and angle regions provides for ideal healing of
fractures in severely atrophic (height < 10 mm) mandibles.
Although load-bearing reconstruction plates enable better
fracture healing and early restoration of function, concomitant
placement of autologous corticocancellous bone grafts is pre-
sumed to increase the osteogenic potential of the native bone
and accelerate healing at the fracture site (Ellis and Price,
2008; Eyrich et al., 1997; Santos et al., 2013; Tiwana et al.,
72 A. Al-Osaimi et al.2009). In the present case, the patient’s systematic status pre-
vented the use of autologous bone.
Surgery combined with physiotherapy and rehabilitation has
been the mainstay of OI treatment (Gallego et al., 2010).Medical
therapies that have been used without proven success include so-
dium ﬂuoride, calcitonin, cortisone, growth hormone, and vita-
mins C and D (Huber, 2007). Bisphosphonate treatment has
had signiﬁcant clinical beneﬁts, such as reduced pain and fracture
incidence and increasedmobility, in children and adolescents with
OI (Rauch and Glorieux, 2005). The therapeutic beneﬁts of bis-
phosphonates are attributed to their inhibitory effects on osteo-
clast formation and activity, and promotion of early osteoclast
apoptosis (Huber, 2007; Landesberg et al., 2009). IVpamidronate
(Rauch and Glorieux, 2005) and oral alendronate (Gallego et al.,
2010) treatments have been reported to increase the long-bone
bone mineral density and decrease the number of fractures in pa-
tients with OI. No signiﬁcant difference has been observed be-
tween oral and IV bisphosphonate therapies in patients with OI
(Gallego et al., 2010). BRONJhas been reported inmany patients
who have received bisphosphonate treatment and undergone oral
surgical procedures (Ruggiero et al., 2009).However, there are no
reported cases of BRONJ in patients with OI treated with bis-
phosphonates, even after dental extraction (Schwartz et al.,
2008). Elevated fasting CTX levels have also been associated with
predictable outcomes following fracture ﬁxation and osseointe-
gration (Marx et al., 2007).Marx et al. (2007) proposed stratiﬁca-
tionof the riskofBRONJ followingoral surgical procedures,with
a fastingCTX level > 150 pg/ml indicating little or no risk, a level
of 100–150 pg/ml indicatingmoderate risk, and a level < 100 pg/
ml indicating high risk. Oral alendronate therapy did not affect
the ﬁnal outcome in the present case.
4. Conclusion
No previous report has described spontaneous fracture of an
atrophic edentulous mandible in a patient with OI. The pa-
tient’s receipt of simultaneous oral bisphosphonate therapy
makes the present case a unique example wherein the clinician
was confronted with difﬁculties in treatment planning and
delivery. The presence of comorbid systemic conditions dictates
the use of techniques proven to be successful, and not those that
are only expected to be successful (Madsen et al., 2011). This
case report highlights the susceptibility of patients with OI to
a fracture of the mandible when it is weakened by physiological
or pathological processes. Nevertheless, the risk of BRONJ in
such patients receiving bisphosphonate therapy cannot be ne-
glected and should be evaluated in long-term clinical studies.
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